Search

Displaying results 4601 - 4610 of 5923 in total
  1. Drug

    Allogeneic processed thymus tissue

    go.drugbank.com/drugs/DB16736
    Approved

    Allogeneic processed thymus tissue is used for immune reconstitution in immune disorders where the patients are severely immunocompromised due to the absence of a functional thymus, such as congenital

  2. Drug

    Imlifidase

    go.drugbank.com/drugs/DB15258
    ApprovedInvestigational

    [A225836] As a result, highly sensitized individuals experience marked delays on transplant lists due to the challenges associated with procuring an HLA compatible donor graft.

  3. Drug

    Maftivimab

    go.drugbank.com/drugs/DB15899
    ApprovedInvestigational

    [A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high

  4. Drug

    Asparaginase Erwinia chrysanthemi

    go.drugbank.com/drugs/DB08886
    ApprovedInvestigational

    Asparaginase _Erwinia chrysanthemi_ and [Asparaginase Escherichia coli] differ in their pharmacokinetic and immunogenic profiles;[L1452] thus, those who are allergic to [Asparaginase Escherichia coli] do

  5. Drug

    Tizaterkib

    go.drugbank.com/drugs/DB21296
    Investigational

    Tizaterkib has a monoisotopic molecular weight of 494.2 Da.

  6. Drug

    Mizacorat

    go.drugbank.com/drugs/DB21458
    Investigational

    Mizacorat has a monoisotopic molecular weight of 494.21 Da.

  7. Drug

    Monlunabant

    go.drugbank.com/drugs/DB21537
    Investigational

    Monlunabant has a monoisotopic molecular weight of 590.11 Da.

  8. Drug

    Iodide I-131

    go.drugbank.com/drugs/DB09293
    ApprovedInvestigational

    Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay.

  9. Drug

    Odesivimab

    go.drugbank.com/drugs/DB15900
    ApprovedInvestigational

    [A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high

  10. Drug

    Cilomilast

    go.drugbank.com/drugs/DB03849
    Investigational

    Following four clinical trials, the drug proved to be effective in treating COPD, however it has never been marketed due to a poor side effect profile.